Literature DB >> 24927525

Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses.

Szun Szun Tay1, Yik Chun Wong2, David M McDonald2, Nicole A W Wood2, Ben Roediger3, Frederic Sierro2, Claire Mcguffog2, Ian E Alexander4, G Alex Bishop5, Jennifer R Gamble6, Wolfgang Weninger7, Geoffrey W McCaughan2, Patrick Bertolino8, David G Bowen9.   

Abstract

CD8 T-cell responses to liver-expressed antigens range from deletional tolerance to full effector differentiation resulting in overt hepatotoxicity. The reasons for these heterogeneous outcomes are not well understood. To identify factors that govern the fate of CD8 T cells activated by hepatocyte-expressed antigen, we exploited recombinant adenoassociated viral vectors that enabled us to vary potential parameters determining these outcomes in vivo. Our findings reveal a threshold of antigen expression within the liver as the dominant factor determining T-cell fate, irrespective of T-cell receptor affinity or antigen cross-presentation. Thus, when a low percentage of hepatocytes expressed cognate antigen, high-affinity T cells developed and maintained effector function, whereas, at a high percentage, they became functionally exhausted and silenced. Exhaustion was not irreversibly determined by initial activation, but was maintained by high intrahepatic antigen load during the early phase of the response; cytolytic function was restored when T cells primed under high antigen load conditions were transferred into an environment of low-level antigen expression. Our study reveals a hierarchy of factors dictating the fate of CD8 T cells during hepatic immune responses, and provides an explanation for the different immune outcomes observed in a variety of immune-mediated liver pathologic conditions.

Entities:  

Keywords:  CTL; TCR; cytotoxicity; rAAV

Mesh:

Substances:

Year:  2014        PMID: 24927525      PMCID: PMC4078818          DOI: 10.1073/pnas.1406674111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

Review 1.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  Molecular mechanisms of portal vein tolerance.

Authors:  Tomohiro Watanabe; Masatoshi Kudo; Tsutomu Chiba; Yoshio Wakatsuki
Journal:  Hepatol Res       Date:  2007-12-09       Impact factor: 4.288

3.  Heterogeneous differentiation patterns of individual CD8+ T cells.

Authors:  Carmen Gerlach; Jan C Rohr; Leïla Perié; Nienke van Rooij; Jeroen W J van Heijst; Arno Velds; Jos Urbanus; Shalin H Naik; Heinz Jacobs; Joost B Beltman; Rob J de Boer; Ton N M Schumacher
Journal:  Science       Date:  2013-03-14       Impact factor: 47.728

4.  Disparate individual fates compose robust CD8+ T cell immunity.

Authors:  Veit R Buchholz; Michael Flossdorf; Inge Hensel; Lorenz Kretschmer; Bianca Weissbrich; Patricia Gräf; Admar Verschoor; Matthias Schiemann; Thomas Höfer; Dirk H Busch
Journal:  Science       Date:  2013-03-14       Impact factor: 47.728

5.  Break of T cell ignorance to a viral antigen in the liver induces hepatitis.

Authors:  D Voehringer; C Blaser; A B Grawitz; F V Chisari; K Buerki; H Pircher
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

6.  Oscillating CD8(+) T cell effector functions after antigen recognition in the liver.

Authors:  Masanori Isogawa; Yoshihiro Furuichi; Francis V Chisari
Journal:  Immunity       Date:  2005-07       Impact factor: 31.745

Review 7.  Adaptive immune responses in acute and chronic hepatitis C virus infection.

Authors:  David G Bowen; Christopher M Walker
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

8.  The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity.

Authors:  David G Bowen; Monica Zen; Lauren Holz; Thomas Davis; Geoffrey W McCaughan; Patrick Bertolino
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

9.  Gene delivery to the juvenile mouse liver using AAV2/8 vectors.

Authors:  Sharon C Cunningham; Allison P Dane; Afroditi Spinoulas; Grant J Logan; Ian E Alexander
Journal:  Mol Ther       Date:  2008-04-15       Impact factor: 11.454

10.  Complete but curtailed T-cell response to very low-affinity antigen.

Authors:  Dietmar Zehn; Sarah Y Lee; Michael J Bevan
Journal:  Nature       Date:  2009-01-28       Impact factor: 49.962

View more
  39 in total

Review 1.  Hepatocytes as Immunological Agents.

Authors:  Ian N Crispe
Journal:  J Immunol       Date:  2016-01-01       Impact factor: 5.422

2.  TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory Recall.

Authors:  Marcin Cebula; Mathias Riehn; Upneet Hillebrand; Ramona F Kratzer; Florian Kreppel; Georgia Koutsoumpli; Toos Daemen; Hansjörg Hauser; Dagmar Wirth
Journal:  Mol Ther       Date:  2017-07-14       Impact factor: 11.454

Review 3.  T-cell exhaustion in allograft rejection and tolerance.

Authors:  Edward B Thorp; Christian Stehlik; M Javeed Ansari
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

4.  Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.

Authors:  Yingjie Bian; Zheng Zhang; Zhichen Sun; Juanjuan Zhao; Danming Zhu; Yang Wang; Sherry Fu; Jingya Guo; Longchao Liu; Lishan Su; Fu-Sheng Wang; Yang-Xin Fu; Hua Peng
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

5.  Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity.

Authors:  Laurent Bartolo; Stéphanie Li Chung Tong; Pascal Chappert; Dominique Urbain; Fanny Collaud; Pasqualina Colella; Isabelle Richard; Giuseppe Ronzitti; Jocelyne Demengeot; David A Gross; Federico Mingozzi; Jean Davoust
Journal:  JCI Insight       Date:  2019-06-06

6.  Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination.

Authors:  Danming Zhu; Longchao Liu; Dan Yang; Sherry Fu; Yingjie Bian; Zhichen Sun; Junming He; Lishan Su; Liguo Zhang; Hua Peng; Yang-Xin Fu
Journal:  J Immunol       Date:  2016-03-02       Impact factor: 5.422

7.  Direct recognition of hepatocyte-expressed MHC class I alloantigens is required for tolerance induction.

Authors:  Moumita Paul-Heng; Mario Leong; Eithne Cunningham; Daniel L J Bunker; Katherine Bremner; Zane Wang; Chuanmin Wang; Szun Szun Tay; Claire McGuffog; Grant J Logan; Ian E Alexander; Min Hu; Stephen I Alexander; Tim D Sparwasser; Patrick Bertolino; David G Bowen; G Alex Bishop; Alexandra Sharland
Journal:  JCI Insight       Date:  2018-08-09

Review 8.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.

Authors:  Helena Costa Verdera; Klaudia Kuranda; Federico Mingozzi
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

9.  Unique CD8+ T Cell-Mediated Immune Responses Primed in the Liver.

Authors:  Jason M Zimmerer; Phillip H Horne; Mason G Fisher; Thomas A Pham; Keri E Lunsford; Bryce A Ringwald; Christina L Avila; Ginny L Bumgardner
Journal:  Transplantation       Date:  2016-09       Impact factor: 4.939

10.  A rational mouse model to detect on-target, off-tumor CAR T cell toxicity.

Authors:  Mauro Castellarin; Caroline Sands; Tong Da; John Scholler; Kathleen Graham; Elizabeth Buza; Joseph A Fraietta; Yangbing Zhao; Carl H June
Journal:  JCI Insight       Date:  2020-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.